or
Bookmark and Share
Agent for regulating the motional function of gastrointestinal tract
   
Document Number
US Patent 4883822
Issued Date
November 28, 1989
Link
Map
Abstract
An agent for regulating the motional function of the gastrointestinal tract, which contains as an active ingredient a 41-metyl-4,4a,9,10-tetrahydro-2(3H)-phenanthrenone derivative represented by the following formula I; ##STR1## wherein R.sup.1 represents a hydrogen atom, an alkyl group or an alkoxy group and R.sup.2 represents a hydrogen atom or an alkyl group.
Tags:
Description:
Amusing 0%
Clever 0%
Complex 0%
Efficient 0%
Historic 0%
Important 0%
Innovative 0%
Interesting 0%
Practical 0%
Simple 0%
Number of Claims:
6
Comments:
no comments yet
Published
November 28, 1989
Application Number
07/248,087
Filed
September 23, 1988
US Classification
514/680  
Int'l Classification
A61K   31/12   (20060101)  
Assistant Examiner
Priority Data
Sep 25, 1987 [JP] 62-240247
USPTO Field of Search
514/680  
Related Patents
6576624 - Use of dopamine receptor antagonists in palliative tumor therapy - Owned by Zentaris AG (Frankfurt am Main,DE)

The side effect of decrease in body weight caused by the alkylphosphocholines such as miltefosine can be antagonized by certain acetylcholine receptor antagonists such as domperidone and pimozide. The combination of alkylphosphocholine plus the antagonist does not have any effect on the anti-tumor action of the alkylphosphocholine. The combination also caused no new side effects in the animals.

6696428 - Use of dopamine receptor antagonists in palliative tumor therapy - Owned by Zentaris AG (Frankfurt/Main,DE)

The side effect of decrease in body weight caused by the alkylphosphocholines such as miltefosine can be antagonized by certain acetylcholine receptor antagonists such as domperidone and pimozide. The combination of alkylphosphocholine plus the antagonist does not have any effect on the anti-tumor action of the alkylphosphocholine. The combination also caused no new side effects in the animals.

5116984 - Imidazole derivatives - Owned by Glaxo Group Limited (London,GB2)

The invention relates to imidazole derivatives of the general formula (I) ##STR1## wherein Im represents an imidazolyl group of formula: ##STR2## A represents the group CH or a nitrogen atom; R.sup.1 and R.sup.2, which may be the same or different, and may be attached to either the same or different fused rings of the naphthalene moiety, each represents a hydrogen atom, a halogen atom, or a hydroxy, C.sub.1-4 alkoxy, C.sub.1-4 alkyl or C.sub.1-4 alkylthio group, and one of R.sup.1 and R.sup.2 may also represent a group --NR.sup.3 R.sup.4 (wherein R.sup.3 and R.sup.4, which may be the same or different, each represents a hydrogen atom or a C.sub.1-4 alkyl group, or together with the nitrogen atom to which they are attached form a saturated 5 to 7 membered ring); n represents 1, 2 or 3; R.sup.5, R.sup.6, R.sup.7, are as defined in the specification; and physiologically acceptable salts and solvates thereof.

Claims
Description
About| FAQs| Terms & Disclaimer| Link to Us| Contact Us